帕金森病分子病理机制研究进展

神经药理学报 ›› 2013, Vol. 3 ›› Issue (2): 35-42.

帕金森病分子病理机制研究进展

张娜, 窦德强

辽宁中医药大学药学院，大连，116600，中国

出版日期:2013-04-26 发布日期:2014-06-27
通讯作者: 窦德强，男，辽宁沈阳人，教授，研究方向：中药化学，Tel：0411-87586014，E-mail：deqiangdou@126.com
作者简介:张娜，女，江苏徐州人，博士研究生，研究方向：中药化学
基金资助:
辽宁省高等学校创新团队课题（LT2013020）

Advances in the Molecular Pathogenesis of Parkinson's Disease

ZHANG Na，DOU De-qiang

College of Pharmacy，Liaoning University of Traditional Chinese Medicine，Dalian 116600，Liaoning，China

Online:2013-04-26 Published:2014-06-27
Contact: 窦德强，男，辽宁沈阳人，教授，研究方向：中药化学，Tel：0411-87586014，E-mail：deqiangdou@126.com
About author:张娜，女，江苏徐州人，博士研究生，研究方向：中药化学
Supported by:
辽宁省高等学校创新团队课题（LT2013020）

摘要/Abstract

摘要： 帕金森病（Parkinson's disease，PD）是一种中老年常见的神经系统退行性疾病，PD的主要病理特点是黑质致密部的多巴胺能神经元丢失，进而使纹状体内的多巴胺水平降低。目前，PD的发病原因尚不完全清楚，本文从遗传因素、环境因素、线粒体功能障碍、氧化应激、氮化应激、免疫炎性反应异常、细胞凋亡学说和神经递质失衡等方面系统总结了近年来PD的病理机制，深入了解 PD 发病机制，为PD的进一步研究提供理论依据。

关键词: 帕金森, 分子水平, 病理机制

Abstract: Parkinson's disease is a common degenerative disease of the nervous system in elderly people. The main pathological features of Parkinson's substantia nigra is the disappearance of dopamine neurons, which reduces the dopamine level in the striatum. This paper summarized the pathogenesis of Parkinson's disease in recent years in several aspects, including genetic factors, environmental factors, mitochondrial dysfunction, oxidative stress, nitrogen stress, abnormal immune inflammatory response, apoptosis doctrine and neurotransmitter imbalances. This review provides a theoretical basis for further study of Parkinson's disease.

Key words: Parkinson, Molecular level, Pathological mechanisms

张娜, 窦德强. 帕金森病分子病理机制研究进展[J]. 神经药理学报, 2013, 3(2): 35-42.

ZHANG Na，DOU De-qiang. Advances in the Molecular Pathogenesis of Parkinson's Disease[J]. Acta Neuropharmacologica, 2013, 3(2): 35-42.

参考文献

[1] Paola Paola. Neurodegenerative movement disorders: the contribution of functional imaging[J]. Curr pin in Neuro, 2004, 17(4):459-466.

[2] Jan Booij, Remco J J Knol. SPECT imaging of the dopaminergic system in (premo-tor) Parkinson’s disease[J]. Parkinsonism Relat Disord, 2007, 13(13):425-428.

[3] Klaus Seppi. MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice[J]. Parkinsonism Relat Disord, 2007; 13(pl3):400-405

[4] Rajput A H, Birdi S. Epidemiology of Parkinson's disease[J]. Parkinsonism & Related Disorders, 1997, 3(4):175-186.

[5]Xiromerisiou G, Hadjigeorgiou G M, Gourbali V, et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson’s disease: identification of two novel LRRK2 variants[J]. Eur J Neurol, 2007, 14(1):7–11.

[6] Guo Ji-feng, Zhang Xue-wei, Nie Li-luo, et al. Mutation analysis of Parkin, PINK1 and DJ-1 genesin Chinese patients with sporadic early onset parkinsonism[J]. J Neurol, 2010, 257(7): 1170-1175.

[7] Peter T Lansbury Jr, Alexis Briee. Geneties of parkinson’s disease and bioehemieal studies of imPlieated gene Produets[J]. Curr Opin Genet Dev, 2002, 12(3):299-306.

[8] Rosa M Canet-Aviles, Mark A Wilson, David W Miller, et al. The Parkinson’s disease protein DJ-1 is neruoprotective due to cysteinesulfinic acid-driven mitochondrial localization[J]. Proc Natl Acad Sci USA, 2004, 101(24):9103-9108.

[9]Ross O A, Soto A I, Vilarino-Guell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease [J]. Disord, 2008, 14(7):539–543.

[10] Carola Schiesling，Nicole Kieper，Kay Seidel，et al．Review: familial Parkinson’s disease genetics，clinical phenotype and neuropathology in relation to the common sporadic form of the disease[J]. Neuropathol Appl Neurobiol, 2008, 34(3):255-271．

[11] Shinji Higashi, Darren J Moore, Rebecca E Colebrooke. et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain[J]. J Neurochem, 2007, 100(2):368–381.

[12] Serge Przedborski, Harry Ischiropoulos. Reactive oxygen and nitrogen species: weapons ofneuronal destruction in models of Parkinson's disease[J]. Antioxid Redox Signal, 2005, 7(5-6):685-693.

[13] David C Dorman, Anna M Mcelveen, Marianne W Marshall, et al. Tissue manganese concentrations inlactating rats and their offspring following combined in utero and lactation exposure to inhaledmanganese sulfate[J]. Toxicol Sci, 2005, 84(1):12-21.

[14] Keiko Imamura, Takao Takeshima, Yoshihiro Kashiwaya, et al. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease[J]. J Neurosci Res, 2006, 84(6):1376-1384.

[15] Hiroshi Kawai, Yukiko Makino, Masaaki Hirobe, et al. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism[J]. J Neurochem, 1998, 70(2):745-751.

[16] Ravindar R Thomas, Paula M Keeney, James P Bennett. Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex[J]. J Parkinsons Dis, 2012, 2(1):67-76.

[17] Laurie H Sanders, J Timothy Greenamyre. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model[J]. Free Radic Biol Med, 2013, 62: 111-120.

[18] 黄桂平. 帕金森病的临床研究及展望[J]. 医学综述，2008，14（13）：2023-2026.

[19] Gail D Zeevalk, Laura P Bernard, William J Nicklas. Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism[J]. J Neurochem, 1998, 70(4): 1421-1430.

[20] Vernica Jackson-Lewis, Michael Jakowec, Robert E Burke, et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine [J]. Neurodegeneration, 1995, 4(3): 257-269.

[21] 项喜艳. DTT诱发内质网应激-自噬过程中活性氧的作用及其调节机制[D].中国优秀博硕士学位论文全文数据库（硕士）：吉林大学，2012.

[22] 王虎，蔡定芳.帕金森病与内质网应激[J]. 国际神经病学神经外科学杂志，2007，34（1）：86-90

[23] 邓娟，白洁. TRPC1和Ca2+在帕金森病内质网应激中的作用[J]. 生命科学，2012，24（10）：1169-1173.

[24] Gail D Zeevalk, Laura P Bernard. Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures [J]. Antioxid Redox Signal, 2005, 7(5-6): 662-672.

[25] Liu Ming-chao, Cai Tong-jian, Zhao Fang, et al. Effect of microglia activation on dopaminergic neuronal injury induced by manganese, and its possible mechanism[J]. Neurotox Res, 2009, 16(1): 42-49.

[26] Verkhratsky A, Toescu E C. Neuronal-glial networks as substrate for CNS integration [J]. J Cell Mol Med, 2006, 10(4):826-836.

[27] Mahmoud M Iravani, Clement C Leung, Mona Sadeghian, et al. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation[J]. Eur J Neurosci, 2005, 22(2): 317-330.

[28] Toshi Nagatsu, Makoto Sawada. Cellular and molecular mechanisms of Parkinson's disease:neurotoxins, causative genes, and inflammatory cytokines[J]. Cell Mol Neurobiol, 2006, 26(4-6): 781-802.

[29] W Michael Caudle, Zhang Jing. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease[J]. Exp Neurol, 2009, 220(2): 230-233.

[30] Patrica A Trimmer, Trisha S Smith, Anthony B Jung, et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity[J]. Neurodegeneration, 1996, 5(3):233-239.

[31] Oren A Levy, Cristina Malagelada, Lloyd A Greene. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps[J]. Apoptosis, 2009, 14(4): 478-500.

[32] Karl Kieburtz, Bernard Ravina. Why hasn't neuroprotection worked in Parkinson's disease[J]. Nat Clin Pract Neurol, 2007, 3(5): 240-241.

[33] Jorg B Schulz. Mechanisms of neurodegeneration in idiopathic Parkinson's disease[J]. Parkinsonism Relat Disord, 2007, 13 (Suppl 3): S306-S308.

[34] Kaivalya J Vyas, John H Weiss. BMAA--an unusual cyanobacterial neurotoxin[J]. Amyotroph Lateral Scler, 2009, 10 (Suppl 2): 50-55.